Fulgent Genetics, Inc. (FLGT) Misses Q2 EPS by 26c

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of $2.55, $0.26 worse than the analyst estimate of $2.81. Revenue for the quarter came in at $153.6 million versus the consensus estimate of $197.34 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2021 EPS of $12.50, versus the consensus of $12.57. Fulgent Genetics, Inc. sees FY2021 revenue of $800 million, versus the consensus of $829 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Limoneira (LMNR) Misses Q2 EPS by 8c, Beats on Revenue